EuroVacc 02 HIV Vaccine trial begins

The European Vaccine Effort against HIV/AIDS, has announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005. These vaccines are based on HIV subtype C, which is prevalent in China, India and sub-Saharan Africa, and constitutes more than 50 percent of the new HIV infections worldwide.

read more:


Popular posts from this blog

Once-Daily 'Male Pill' Shows Promise in Early Study

Inflammatory Bowel Disease an Independent Risk Factor for MI

Inflamation and Alzheimer disease